2020 Aug 10;15(8):e0237525. Epub 2017 Sep 2.J Med Virol.
1992 Jun;21(3):564-73. doi: 10.1093/ije/21.3.564.Wong VC, Ip HM, Reesink HW, Lelie PN, Reerink-Brongers EE, Yeung CY, Ma HK.Lancet. These initial results indicate that combined passive and active immunization is efficacious in interrupting perinatal transmission of HBV infection. Epub 2007 Feb 28.de Villiers MJ, Gamkrelidze I, Hallett TB, Nayagam S, Razavi H, Razavi-Shearer D.PLoS One. 1.HBV carriers had significantly higher levels of AST (26.9 ± 14.0 vs 22.1 ± 8.3 U/L, P < 0.001) and ALT (34.0 ± 30.4 vs 24.3 ± 17.0 U/L, P < 0.001) compared to non-carriers. Blood tests can detect signs of the hepatitis B virus in your body and tell your doctor whether it's acute or chronic.
Locally, 6% of the Singapore population are hepatitis B carriers. 2007 Jun;12(3):160-7. doi: 10.1016/j.siny.2007.01.013. 2. doi: 10.1093/ofid/ofaa137. There were no significant differences between HBV carriers and non-carriers with respect to age, BMI, and waist circumference. Group I received HBV vaccine alone while Group II received HBV vaccine in combination with HBIG at birth and group III received HBV vaccine plus HBIG at birth and again at one month old. COVID-19 is an emerging, rapidly evolving situation. Unable to load your collection due to an error The antibody to HBsAg (anti-HBs) positivity rate in sera of Group I, II, III infants at 6 months of age was 79.0%, 88.9% and 94.7%, respectively. Compared with 90% of infants who became HBV carriers in the control group (Group IV), the efficacy of HBV vaccination in preventing HBV infection among these high risk infants at the 6th month was 73.7% in Group I, 87.7% in Group II, and 94.1% in Group III. Please enable it to take advantage of the complete set of features! eCollection 2020.Open Forum Infect Dis. The protective efficacy of a recombinant DNA yeast-derived hepatitis B vaccine was assessed alone or in combination with hepatitis B immune globulin (HBIg) in neonates born to surface antigen (HBsAg)-positive and e antigen (HBeAg)-positive mothers. Neonates received either a 10 micrograms dose of va …
We attempted a clinical trial to interrupt transmission of hepatitis B virus (HBV) infection from hepatitis B surface antigen (HBsAg) positive and hepatitis Be antigen (HBsAg) positive mothers to their infants in Taiwan.
1984 Apr 28;1(8383):921-6. doi: 10.1016/s0140-6736(84)92388-2.Stevens CE, Toy P, Kamili S, Taylor PE, Tong MJ, Xia GL, Vyas GN.Biologicals.
3.
At 6 months of age, the HBV carrier rate was 23.7% (9/38) in Group I, 11.1% (4/36) in Group II, and 5.3% (2/38) in Group III infants.
A simple blood test can also determine if you're immune to the condition. Screening for hepatitis B is recommended …
2017 Nov;50:3-19. doi: 10.1016/j.biologicals.2017.08.008.
2013 Nov;7(3):333-40. doi: 10.12816/0006062.Poovorawan Y, Chongsrisawat V, Theamboonlers A, Leroux-Roels G, Kuriyakose S, Leyssen M, Jacquet JM.J Viral Hepat. Yang YJ, Liu CC, Chen TJ, Lee MF, Chen SH, Shih HH, Chang MH.Pediatr Infect Dis J. 1994 Sep;12(12):1059-63. doi: 10.1016/0264-410x(94)90173-2.Halliday ML, Kang LY, Rankin JG, Coates RA, Corey PN, Hu ZH, Zhou TK, Yuan GJ, Yao FL.Int J Epidemiol. Pediatrics 1982;70:557-9.
doi: 10.1371/journal.pone.0237525. eCollection 2020 May.Chen ZX, Zhuang X, Zhu XH, Hao YL, Gu GF, Cai MZ, Qin G.Open Forum Infect Dis. We attempted a clinical trial to interrupt transmission of hepatitis B virus (HBV) infection from hepatitis B surface antigen (HBsAg) positive and hepatitis Be antigen (HBsAg) positive mothers to their infants in Taiwan. The results obtained in the subgroups categorized by HBVC and SFL are shown in Table Table1.